Novo CFO: Obesity market is difficult to predict
Although there is a market for weight loss treatments, and Novo Nordisk has already experienced huge demand for obesity drug Wegovy, the market still needs to be developed over coming years. For this reason, Novo Nordisk’s 2025 predictions are considerably lower than the analyst consensus.
by ALBERT RØNNING-ANDERSSON, translated by daniel pedersen
While equity analysts predict that Novo Nordisk’s obesity drug sales will reach DKK 40bn (USD 5.9bn) in 2025, the company itself is only forecasting 2025 sales of ”over DKK 25bn (USD 3.7bn, ed.),” CFO Karsten Munk Knudsen tells Danish business daily Børsen.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
.jpg&w=384&q=75)
